Tier 4 — mechanistic

Betaine as a regulator of metabolism, epigenetics, and cellular osmoprotection: therapeutic implications in cardiometabolic and renal diseases

Sumet Kumar Singh, Poonam Yadav, Manish Bishnolia, Nirmal Manhar, Puneet Kumar, Umashanker Navik, Ralf Weiskirchen
Frontiers in pharmacology 2026 17:1883688

Bibliography

PubMed
PMID 42602094
PubMed Central
PMC13473388
DOI
10.3389/fphar.2026.1883688
Funding
Reported funding/support: The author(s) declared that financial support was received for this work and/or its publication. PY thanks the Indian Council of Medical Research (ICMR: Ref No. 45/04/2022-PHA/BMS), Government of India, for providing an SRF fellowship to support her PhD work in the Department of Pharmacology at CUPB. UN thanks the Indo-German Science and Technology Center (IGSTC/PECFAR/Call 2022/US-AK/36/2022–23/Award letter/488) for providing the Paired Early Career Fellowship in Applied Research (PECFAR) fellowship.
Competing interests
Reported disclosure: RW is an editorial board member of Frontiers in Pharmacology and an associate editor of Frontiers in Cellular and Infection Microbiology and Frontiers in Drug Delivery. However, he was not involved in any stage of the editorial process, including reviewer selection, manuscript handling, or decision-making. The remaining authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Study snapshot

DesignNarrative review
ModelEvidence synthesis; mixed research models
SamplePublished literature; no newly enrolled participant cohort
InterventionReview of betaine-related evidence; no single assigned intervention
DurationEvidence review; source-specific study durations vary
EndpointsBetaine biology; Clinical and mechanistic evidence

What the study showed, in plain terms

Published in 2026, this source examined mechanistic and clinical reviews. Its evidence base was Published literature; no newly enrolled participant cohort. It evaluated Review of betaine-related evidence; no single assigned intervention across Evidence review; source-specific study durations vary.

Reviews methyl donation, osmotic protection and proposed cardiometabolic, liver and renal mechanisms.

Claims span different formulations and evidence levels. Preclinical promise and HCl acidification should not be treated as proven anhydrous-TMG disease benefits.

Continue with TMG Data Center

Continue with TMG, Methylation and MTHFR: Understanding the Evidence

Key findings

  • Reviews methyl donation, osmotic protection and proposed cardiometabolic, liver and renal mechanisms.
  • The recorded outcome domains were Betaine biology; Clinical and mechanistic evidence.

What this study can and cannot tell us

  • Claims span different formulations and evidence levels. Preclinical promise and HCl acidification should not be treated as proven anhydrous-TMG disease benefits.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Accessible full-text extract plus indexed bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Decoding Betaine: A Critical Analysis of Therapeutic Potential Compared with Marketing Hype-A Narrative Review
Grzegorz Nikrandt et al. · The Journal of nutrition · 2024
Tier 4
Beneficial Effects of Betaine: A Comprehensive Review
Madan Kumar Arumugam et al. · Biology · 2021
Tier 4
Betaine in human nutrition
Stuart A S Craig et al. · The American journal of clinical nutrition · 2004
Tier 4
Choline and betaine in health and disease
Per Magne Ueland et al. · Journal of inherited metabolic disease · 2011

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology